Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals Ltd has approved the exercise of 517,795 Special Rights, leading to the issuance of 517,795 new shares for a total subscription price of EUR 965,998.35. These shares have been registered in the Finnish Trade Register, bringing the total number of ordinary shares to 118,563,143. The new shares are expected to commence trading on First North and AIM around December 5, 2025, potentially impacting the company’s market presence and shareholder dynamics.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. The company’s lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody aimed at removing immunosuppression of cancers by reprogramming myeloid cell function. Bexmarilimab is currently being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Find detailed analytics on FARN stock on TipRanks’ Stock Analysis page.